Management of Colorectal Cancer in Elderly Patients: Focus on the Cost of Chemotherapy

Drugs and Aging

Volumn 21, Issue 2, 2004, Pages 113-133

  Matasar, Matthew J ^a   Sundararajan, Vijaya ^b   Grann, Victor R ^a,c   Neugut, Alfred I ^a,c,d  

^a Columbia University ^*  (United States)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^c PH 18 127 ^*  (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CHLORMETHINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; RALTITREXED; UFT; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; AGING; ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; FOLLOW UP; HEPATIC ARTERY; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SEPSIS; SOLID TUMOR; STOMATITIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; FLUOROURACIL; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 1442310994     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421020-00004     Document Type: Review

References (97)

1. Vercelli M, Quaglia A, Casella C, et al. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1998; 34: 2264-70
2. Furner SE, Brody JA, Jankowski LM: Epidemiology and aging. In: Cassel CK, Cohen HJ, Larson EB, et al., editors. Geriatric medicine. 3rd ed. New York (NY): Springer, 1997: 37-43
3. Miller BA, Ries LAG, Hankey BF, et al., editors. SEER cancer statistics review: 1973-1990. Bethesda (MD): National Cancer Institute, 1993
4. National Center for Chronic Disease Prevention and Health Promotion. National program of cancer registries: background [online]. Available from URL: http://www.cdc.gov/cancer/ npcr/uscs/report/technical_notes/background.htm [Accessed 2003 Oct 7]
5. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002; 94: 2766-92
6. National Cancer Institute. Cancer progress report 2001 [online]. Available from URL: http://progressreport.cancer.gov [Accessed 2003 Oct 7]
7. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-8
8. Violi V, Pietra N, Grattarola M, et al. Curative surgery for colorectal cancer: long-term results and life expectancy in the elderly. Dis Colon Rectum 1998; 41: 291-8
9. Wingo PA, Gloeckler Ries LA, Parker SL, et al. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7: 271-82
10. Arveux I, Boutron MC, Mrini TE, et al. Colon cancer in the elderly: evidence for major improvements in health care and survival. Br J Cancer 1997; 76: 963-7
11. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998; 34: 2176-83
12. Fielding LP, Phillips RKS, Hittinger R. Factors influencing mortality after curative resection for large bowel cancer in elderly patients. Lancet 1989; 8638: 595-7
13. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580-4
14. Irvin TT. Prognosis of colorectal cancer in the elderly. Br J Surg 1988; 75: 419-21
15. Shankar A, Taylor I. Treatment of colorectal cancer in patients aged over 75. Eur J Surg Oncol 1998; 24: 391-5
16. Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000; 356: 968-74
17. Audisio RA, Cazzaniga M, Robertson C, et al. Elective surgery for colorectal cancer in the aged: a clinical-economical evaluation. Br J Cancer 1997; 78: 382-4
18. Nelson H, Weeks J, Wieand HS. Proposed phase in trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr 1995; 19: 51-6
19. Stead ML, Brown JM, Bodanquet N, et al. Assessing the relative costs of standard open surgery and laparoscopic surgery in colorectal cancer in a randomized controlled trial in the United Kingdom. Crit Rev Oncol Hematol 2000; 33: 99-103
20. Weeks J, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: a randomized trial. JAMA 2002; 287: 321-8
21. Briunvels DJ, Stiggelbrut AM, Kievit J. Follow-up of patients with colorectal cancer: a metaanalysis. Ann Surg 1994; 219: 174-82
22. Lautenbach E, Forde KA, Neugut AI. Benefits of colonoscopic surveillance after curative resection of colorectal cancer. Ann Surg 1994; 220: 206-11
23. Ovaska J, Larvinen H, Kujari H, et al. Follow-up of patients operated on for colorectal carcinoma. Am J Surg 1990; 159: 593-6
24. Makela J, Laitinen S, Kairaluoma I. Early results of follow-up after radical resection for colorectal cancer. Surg Oncol 1992; 1: 157-61
25. Tornqvist A, Ekelund G, Leandoer L. The value of intensive follow-up after curative resection for colorectal carcinoma. Br J Surg 1982; 69: 725-8
26. Rosen M, Chan L, Beart RW, et al. Follow-up of colorectal cancer: ameta-analysis. Dis Colon Rectum 1998; 41: 1116-26
27. Virgo KS, Vernava AM, Longo WE, et al. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995; 273 (23): 1837-41
28. Graham RA, Wamg S, Catalano PJ, et al. Postsurgical surveillance of colon cancer. Ann Surg 1998; 228: 59-63
29. Castells A, Bessa X, Daniels M, et al. Value of postoperative surveillance after radical surgery for colorectal cancer. Dis Colon Rectum 1998; 41: 714-24
30. Ketteniß M, Schütz G, Ulrich B. Costs and efficiency of a tumor follow-up program for the detection of colorectal liver metastases. Int J Colorectal Dis 2001; 16: 28-31
31. Macdonald JS, Astrow AB. Adjuvant therapy of colon cancer. Semin Oncol 2001; 28: 30-40
32. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal cancer. Cancer 1990; 64: 49-55
33. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988; 259: 3571-8
34. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-7
35. Treurniet-Donker AD, van Putten WLJ, Wereldsma JCJ, et al. Postoperative radiation therapy for rectal cancer an interim analysis of a preoperative randomized multicenter trial in the Netherlands. Cancer 1991; 67: 2042-8
36. Jansson Frykholm GH, Flimelius B, Påhlman L. Preoperative and postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36: 564-72
37. Tveit KM, Guldvog I, Hagen S, et al. Randomized controlled trial of postoperative radiotherapy and shortterm time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Br J Surg 1997; 84: 11330-5
38. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-15
39. National Cancer Institute. Colon cancer (PDQ®): treatment [online]. Available from URL: http://www.cancer.gov/cancer-info/pdq/treatment/colon/ healthprofessional/ [Accessed 2003 Oct 7]
40. Tannock F. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 3156-74
41. Hafstrom L, Domellof L, Rudenstam CM, et al. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 1984; 310: 737-43
42. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer. J Natl Cancer Inst 1988; 80: 30-6
43. Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569-72
44. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87
45. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-50
46. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1995; 75: 11-7
47. Forman WB. The role of chemotherapy and adjuvant therapy in the management of colorectal cancer. Cancer 1995; 74: 2151-3
48. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385-90
49. Jessup JM, McGinnis LS, Steele GD, et al. The national cancer database: report on colon cancer. Cancer 1996; 78: 918-26
50. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colorectal cancer in the elderly: a population-based study. Cancer J 2001; 7: 213-8
51. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447-56
52. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50
53. Moertel C, Fleming T, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8
54. Dubé S, Heyen F, Jeicek M. Adjuvant chemotherapy in colorectal carcinoma. Dis Colon Rectum 1997; 40: 35-41
55. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-9
56. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588-96
57. Advanced Colorectal Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903
58. Ragnhammar P, Hafström L, Nygren P, et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308
59. Caudry M, Bonnel C, Floquet A, et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995; 18: 118-25
60. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: French Intergroup Study. J Clin Oncol 1997; 15: 808-15
61. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996; 19: 371-4
62. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-8
63. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-7
64. Daniele B, Simmonds PD, Best LY, et al. Current controversies in cancer: should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age? Eur J Cancer 1999; 35: 1640-9
65. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage in colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994; 86: 424-30
66. Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost effectiveness analysis. Ann Oncol 1997; 8: 65-70
67. Smith RD, Hall J, Gurney H, et al. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Med J Aust 1993; 158: 319-22
68. Lokich JL, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors: Part I. model projections for cost based on charges. Cancer 1996; 78: 294-9
69. Lokich JL, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: Part II. use of charges versus reimbursement for cost basis. Cancer 1996; 78: 300-3
70. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996; 32A Suppl. 5: S13-7
71. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74
72. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastasis from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77 (11): 1241-6
73. Steele G, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver. J Clin Oncol 1991; 9: 1105-12
74. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-8
75. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 1997; 89: 790-5
76. Anderson H, Palmer MK. Measuring quality of life: impact of chemotherapy for advanced colorectal cancer: experience from two recent large phase III trials. Br J Cancer 1998; 77 Suppl. 2: 9-14
77. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 13: 1128-35
78. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-9
79. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-95
80. Cunningham D, Pyrhönen S, James R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8
81. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12
82. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14
83. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-5
84. Van Custem E, Douillard JY. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351-2
85. Levy-Piedbois C, Durand-Zaleski I, Juhel H, et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000; 11: 157-61
86. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16: 2977-85
87. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase in study. J Clin Oncol 2001; 19: 2282-92
88. Hoff PM. Capecitabine as first-line treatment for colorectal cancer: integrated results of 1207 patients from 2 randomized, phase III studies [abstract 263PD]. On behalf of the Capecitabine CRC Study Group. Ann Oncol 2000; 11 Suppl. 4: 60
89. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
90. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6
91. Blackledge G. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer 1998; 77 Suppl. 2: 29-37
92. Cunningham D, Zalcberg JR, Rath U, et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945-54
93. Cunningam D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77 Suppl. 2: 15-21
94. Comella P, De Vita F, Mancarella S, et al. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 2000; 11 (10): 1323-33
95. Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359 (9317): 1555-63
96. Kim DJ, Kim TI, Suh JH, et al. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei Med J 2003; 44 (4): 665-75
97. Murad A, de Andrade CA, Delfino C, et al. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Huntingt) 1997; 11 Suppl. 10: 128-35